Alkermes Q2 revenue falls to $390.7 million; 2025 financial expectations reiterated
Alkermes reported second quarter 2025 results, with total revenues of $390.7 million, down from $399.1 million a year earlier, and GAAP net income from continuing operations of $87.1 million, down from $94.7 million. Proprietary product net sales rose to $307.2 million from $269.3 million, but the decline in manufacturing and royalty revenues drove the overall drop, and the company reiterated its 2025 financial expectations.
Key points
- Total revenues were $390.7 million versus $399.1 million in the second quarter of 2024.
- GAAP diluted earnings per share from continuing operations were $0.52, compared with $0.55 a year earlier.
- Proprietary net sales rose to $307.2 million, with LYBALVI at $84.3 million and ARISTADA at $101.3 million.
- The company reiterated 2025 total revenue expectations of $1,340 million to $1,430 million, as set forth in its February 12, 2025 release.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.